Leukemia. 7 December 2016: S Rafiq, T J Purdon, A F Daniyan, M Koneru, T Dao, C Liu, D A Scheinberg & R J Brentjens
The Journal of Clinical Investigation. 19 June 2017: Aaron Y. Chang, Tao Dao, Ron S. Gejman, Casey A. Jarvis, Andrew Scott, Leonid Dubrovsky, Melissa D. Mathias, Tatyana Korontsvit, Victoriya Zakhaleva, Michael Curcio, Ronald C. Hendrickson, Cheng Liu, and David A. Scheinberg
Clinical Cancer Research. 15 January 2017: Hong Liu, Yiyang Xu, Jingyi Xiang, Li Long, Shon Green, Zhiyuan Yang, Bryan Zimdahl, Jingwei Lu, Neal Cheng, Lucas H Horan, Bin Liu, Sun Yan, Pei Wang, Juan Diaz, Lu Jin,Yoko Nakano, Javier F Morales, Pengbo Zhang, Lian-xing Liu, Binnaz K Staley, Saul J Priceman, Christine E. Brown, Stephen J. Forman, Vivien W Chan & Cheng Liu
Oncoimmunology. 3 August 2016: Leonid Dubrovsky, Elliott Joseph Brea, Dmitry Pankov, Emily Casey, Tao Dao, Cheng Liu, and David A. Scheinberg
Journal of Molecular Biology. 16 January 2016: Niloufar Ataie, Jingyi Xiang, Neal Cheng, Elliott J. Brea, Wenjie Lu, David A. Scheinberg, Cheng Liu, and Ho Leung Ng
Peptide Antibodies. Methods in Molecular Biology, vol 1348. Humana Press, New York, NY (2015): Brian H. Santich, Hong Liu, Cheng Liu & Nai-Kong V. Cheung
Nature Biotechnology. 21 September 2015: Tao Dao, Dmitry Pankov, Andrew Scott, Tatyana Korontsvit, Victoriya Zakhaleva, Yiyang Xu, Jingyi Xiang, Su Yan, Manuel Direito de Morais Guerreiro, Nicholas Veomett, Leonid Dubrovsky, Michael Curcio, Ekaterina Doubrovina, Vladimir Ponomarev, Cheng Liu, Richard J O’Reilly & David A Scheinberg
Clinical Cancer Research. 31 July 2014: Nicholas Veomett, Tao Dao, Hong Liu, Jingyi Xiang, Dmitry Pankov, Leonid Dubrovsky, Joseph A. Whitten, Sun-Mi Park, Tatyana Korontsvit, Victoria Zakhaleva, Emily Casey, Michael Curcio, Michael G. Kharas, Richard J. O’Reilly, Cheng Liu, and David A. Scheinberg
Blood. 6 December 2014: Sarwish Rafiq, Tao Dao, Cheng Liu, David A. Scheinberg, and Renier J Brentjens
November 7th, 2014: Ching-Wen Hsiao, Yen-Ting Lo, Hong Liu, and Sonny C Hsiao
Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.
Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.
Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.